Rottlerin: Bases for a Possible Usage in Psoriasis

Title: Rottlerin: Bases for a Possible Usage in Psoriasis

Volume: 11 Issue: 5

Author(s): Emanuela Maioli and Giuseppe Valacchi

Affiliation:

Keywords: Rottlerin, NFκB, Inflammation, Angiogenesis, Proliferation

Abstract: Rottlerin is a natural polyphenolic compound, which was initially indicated and marketed as a PKC δ inhibitor and recently proposed and patented as an anti-hypertensive drug. In vitro results from our Laboratory and data from the literature suggest a potential use of Rottlerin in the treatment/control of psoriasis, a skin disease characterized by abnormal cellular proliferation, abnormal angiogenesis and inflammation. Rottlerin, indeed, is an antioxidant and a potent inhibitor of the transcription factor NFκB, a key mediator of immune responses and a crucial regulator of cell cycle and apoptosis in immune cells, endothelial cells and keratinocytes. Herein, we will review the multiple activities of Rottlerin (antioxidant, antiproliferative, antiangiogenic and anti-inflammatory) that give to the drug the potential to be used as a new therapeutic approach against psoriasis.

Cite this article as:

Maioli Emanuela and Valacchi Giuseppe, Rottlerin: Bases for a Possible Usage in Psoriasis, Current Drug Metabolism 2010; 11 (5) . https://dx.doi.org/10.2174/138920010791526097